Palbociclib-d4 (hydrochloride)

Palbociclib-d4 (hydrochloride)

• UNSPSC Description: Palbociclib-d4 (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].
• Target Antigen: CDK; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Cell Cycle/DNA Damage;Others
• Field of Research: Cancer
• Solubility: 10 mM in DMSO
• Smiles: O=C1C(C(C)=O)=C(C2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(N5CC([2H])([2H])NC([2H])([2H])C5)C=N4)C.Cl
• Molecular Weight: 488.02
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.|[3]Katsumi Y, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun, 2011, 413(1), 62-68.|[4]Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471-475.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported